We are live on
!
Find out more
OPPM
Opus Point Partners Management Portfolio holdings
AUM
$55.3M
1-Year Est. Return
7.48%
This Fund
S&P 500
This Quarter
Est. Return
-15.77%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$181M
AUM Growth
+$54.8M
(+43%)
Cap. Flow
+$26.4M
Cap. Flow
% of AUM
14.57%
Top 10 Holdings %
Top 10 Hldgs %
55.68%
Holding
69
New
12
Increased
29
Reduced
12
Closed
12
Avg Time Held Equity + Options
2.1
quarters
Top 10 Avg Time Held Equity + Options
0.6
quarters
Top 20 Avg Time Held Equity + Options
2.1
quarters
Avg Time Held Equity only
2.2
quarters
Top 10 Avg Time Held Equity only
0.9
quarters
Top 20 Avg Time Held Equity only
2.3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Biotechnology ETF
IBB
|
+$7.2M |
| 2 |
Agios Pharmaceuticals
AGIO
|
+$4.5M |
| 3 |
MDVN
MEDIVATION, INC.
MDVN
|
+$2.46M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$2.28M |
| 5 |
Merck
MRK
|
+$2.28M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
+$5.34M |
| 2 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
+$1.78M |
| 3 |
TSRO
TESARO, Inc.
TSRO
|
+$1.76M |
| 4 |
Pacira BioSciences
PCRX
|
+$1.59M |
| 5 |
Esperion Therapeutics
ESPR
|
+$1.23M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.5% |
| 2 | Miscellaneous | 40.37% |
| 3 | Financials | 0.14% |
| 4 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
| $53.7M | 29.65% |
862,500
+859,500
| +28,650% | +$67.7M |
2015 Q2
1 quarter
|
|
|
2
iShares Biotechnology ETF
IBB
$10.5B
| $6.07M | 3.35% |
+60,000
| New | +$7.2M |
2015 Q3
0 quarters
|
|
|
CLVS
3
DELISTED
Clovis Oncology, Inc.
CLVS
| $5.39M | 2.97% |
58,567
+6,167
| +12% | +$534K |
2014 Q4
3 quarters
|
|
4
Incyte
INCY
$22.7B
| $5.23M | 2.89% |
47,400
+5,527
| +13% | +$620K |
2014 Q4
3 quarters
|
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
| $5.16M | 2.85% |
33,021
+11,547
| +54% | +$2.11M |
2014 Q4
3 quarters
|
|
|
CELG
6
DELISTED
Celgene Corp
CELG
| $5.1M | 2.82% |
47,137
+8,762
| +23% | +$1.09M |
2014 Q4
3 quarters
|
|
7
Biogen
BIIB
$34.3B
| $5.1M | 2.81% |
17,467
+6,213
| +55% | +$2.05M |
2014 Q4
3 quarters
|
|
8
Alkermes
ALKS
$6.74B
| $5.1M | 2.81% |
86,864
+15,842
| +22% | +$1.05M |
2014 Q4
3 quarters
|
|
|
MDVN
9
DELISTED
MEDIVATION, INC.
MDVN
| $5.03M | 2.78% |
118,372
+49,684
| +72% | +$2.46M |
2014 Q4
3 quarters
|
|
10
Illumina
ILMN
$41.6B
| $4.98M | 2.75% |
29,127
+7,075
| +32% | +$1.43M |
2014 Q4
3 quarters
|
|
11
Regeneron Pharmaceuticals
REGN
$78.8B
| $4.94M | 2.73% |
10,627
+1,868
| +21% | +$1M |
2014 Q4
3 quarters
|
|
12
Nektar Therapeutics
NKTR
$1.37B
| $4.87M | 2.69% |
29,617
+5,086
| +21% | +$900K |
2014 Q4
3 quarters
|
|
|
SGEN
13
DELISTED
Seagen Inc. Common Stock
SGEN
| $4.8M | 2.65% |
124,558
+20,219
| +19% | +$910K |
2014 Q4
3 quarters
|
|
14
BioMarin Pharmaceuticals
BMRN
$10.8B
| $4.42M | 2.44% |
42,012
+6,113
| +17% | +$817K |
2014 Q4
3 quarters
|
|
15
Bio-Techne
TECH
$11.4B
| $4.35M | 2.4% |
188,000
+52,000
| +38% | +$1.3M |
2014 Q4
3 quarters
|
|
16
AstraZeneca
AZN
$246B
| $4.33M | 2.39% |
68,000
+18,000
| +36% | +$1.18M |
2015 Q2
1 quarter
|
|
17
Mettler-Toledo International
MTD
$31.3B
| $4.33M | 2.39% |
15,200
+4,200
| +38% | +$1.33M |
2014 Q4
3 quarters
|
|
18
Vertex Pharmaceuticals
VRTX
$129B
| $4.26M | 2.35% |
40,876
+5,600
| +16% | +$719K |
2014 Q4
3 quarters
|
|
|
QGENF
19
DELISTED
QIAGEN NV
QGENF
| $4.13M | 2.28% |
160,000
+20,000
| +14% | +$516K |
2014 Q4
3 quarters
|
|
20
Ionis Pharmaceuticals
IONS
$7.28B
| $4.1M | 2.26% |
101,401
+35,193
| +53% | +$1.82M |
2014 Q4
3 quarters
|
|
|
CPHD
21
DELISTED
Cepheid Inc
CPHD
| $4.07M | 2.25% |
90,000
+26,365
| +41% | +$1.41M |
2014 Q4
3 quarters
|
|
22
Alnylam Pharmaceuticals
ALNY
$30.4B
| $3.89M | 2.15% |
48,448
+13,469
| +39% | +$1.5M |
2014 Q4
3 quarters
|
|
|
23
Agios Pharmaceuticals
AGIO
$1.85B
| $3.25M | 1.79% |
+46,000
| New | +$4.5M |
2015 Q3
0 quarters
|
|
|
24
Bristol-Myers Squibb
BMY
$117B
| $2.13M | 1.18% |
+36,000
| New | +$2.28M |
2015 Q3
0 quarters
|
|
|
25
Merck
MRK
$359B
| $2.02M | 1.12% |
+42,968
| New | +$2.28M |
2015 Q3
0 quarters
|
|
Similar funds
KIA
PGA
GX
SCG
TCMV
FCM
DP
SAM
Opus Point Partners Management's Q3 2015 Portfolio in Review
As of Q3 2015, Opus Point Partners Management held 69 positions worth $181M, up 43% from $126M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Opus Point Partners Management deployed $26.4M of net new capital in Q3 2015, opening 12 new positions and adding to 29 existing holdings. Its largest new stake was iShares Biotechnology ETF: 60,000 shares worth $6.07M.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 83% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was ProShares Ultra NASDAQ Biotechnology, an estimated $1.78M trimmed.
- Opus Point Partners Management's largest Q3 2015 buy was iShares Biotechnology ETF: 60,000 shares worth $6.07M.
- Opus Point Partners Management added most to MEDIVATION, INC. in Q3 2015, an estimated $2.46M increase.
- Opus Point Partners Management's biggest Q3 2015 reduction was ProShares Ultra NASDAQ Biotechnology, cutting an estimated $1.78M.
- Opus Point Partners Management fully exited RECEPTOS INC COM STK (DE) in Q3 2015, selling an estimated $5.34M.
- Opus Point Partners Management's ten largest holdings make up 56% of its $181M portfolio in Q3 2015.
- Opus Point Partners Management opened 12 new positions and closed 12 in Q3 2015.
- Opus Point Partners Management's portfolio value rose 43% quarter-over-quarter to $181M.
Based on Opus Point Partners Management's 13F filing for Q3 2015, filed 16 Nov 2015.